- Country: Czech Republic
- Summary: Monoclonal Antibody - Daratumumab I.
- CZT Ref No: 131373023
- Deadline: 08 Jan 2026
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: CZK 19673000
- Notice Type: Tender
- Document Ref. No.: 802986-2025
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- The subject of the public contract is the supply of a medicinal product for parenteral administration containing the monoclonal antibody IgG1kappa daratumumab (ATC group L01FC01) for the treatment of patients in approved indications according to the SPC valid on the date of submission of bids and in off-label administration after prior approval by the review doctor of the health insurance company.
Monoclonal antibody - Daratumumab I.
Doc Title: Monoclonal antibody - Daratumumab I.
Contract Type: supplies - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINMonoclonal Antibody - Daratumumab I. - Czech Republic Tender
The INSTITUTE OF CLINICAL AND EXPERIMENTAL MEDICINE, a Government sector organization in Czech Republic, has announced a new tender for Monoclonal Antibody - Daratumumab I.. This tender is published on CzechRepublicTenders under CZT Ref No: 131373023 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2026-01-08.
The estimated tender value is CZK 19673000, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
